A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications.
Phase of Trial: Phase III
Latest Information Update: 27 Oct 2016
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms GWCO
- Sponsors AstraZeneca; Bristol-Myers Squibb
- 10 Jun 2017 Biomarkers information updated
- 23 Mar 2012 A supplemental marketing authorisation application has been submitted to the EMA for use of exenatide as add-on therapy to basal insulin and was subsequently approved by the European Commission, according to an Amylyn media release.
- 28 Jun 2011 Bodyweight outcomes presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History